| abstract |
Novel substituted indoloquinoxalines of formulaI, wherein R<1> is hydrogen or represents one or more similar or different substituents in the positions 7 to 10 selected from the group halogen, lower alkyl/alkoxy, hydroxy, trifluoromethyl, trichloromethyl, trifluoromethoxy, R<2> represents similar or different C1-C4 alkyl substituents, X is CO or CH2, Y is OH, NH2, NH-(CH2)n-R<3> wherein R<3> represents lower alkyl, OH, NH2, NHR<4> or NR<5>R<6> wherein R<4>, R<5> and R<6> independently are lower alkyl or cycloalkyl and n is an integer of from 2 to 4, with the provision that when X is CH2, Y is OH or NH-(CH2)n-OH, and pharmacologically acceptable salts thereof are described. The compounds are useful as drugs for preventing and/or treating autoimmune diseases. |